
Global Live Attenuated Measles Vaccine Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.
Live Attenuated Measles Vaccine Segment by Company
GSK
Bavarian Nordic
CSL Limited
Emergent Biosolutions
Medimmune
Sanofi-Pasteur
Serum Institute of India
Beijing Institute of Biological Products Co., Ltd
Pfizer
Lanzhou Institute of Biological Products Co., Ltd
Merck
Novartis
Johnson & Johnson
Shanghai Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Measles Vaccine Segment by Type
Liquid
Powder
Live Attenuated Measles Vaccine Segment by Application
Hospital
Clinic
Live Attenuated Measles Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Live Attenuated Measles Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Measles Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
According to APO Research, The global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.
Live Attenuated Measles Vaccine Segment by Company
GSK
Bavarian Nordic
CSL Limited
Emergent Biosolutions
Medimmune
Sanofi-Pasteur
Serum Institute of India
Beijing Institute of Biological Products Co., Ltd
Pfizer
Lanzhou Institute of Biological Products Co., Ltd
Merck
Novartis
Johnson & Johnson
Shanghai Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Measles Vaccine Segment by Type
Liquid
Powder
Live Attenuated Measles Vaccine Segment by Application
Hospital
Clinic
Live Attenuated Measles Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Live Attenuated Measles Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Measles Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Table of Contents
200 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Live Attenuated Measles Vaccine Market by Type
- 1.2.1 Global Live Attenuated Measles Vaccine Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Liquid
- 1.2.3 Powder
- 1.3 Live Attenuated Measles Vaccine Market by Application
- 1.3.1 Global Live Attenuated Measles Vaccine Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Live Attenuated Measles Vaccine Market Dynamics
- 2.1 Live Attenuated Measles Vaccine Industry Trends
- 2.2 Live Attenuated Measles Vaccine Industry Drivers
- 2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
- 2.4 Live Attenuated Measles Vaccine Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Live Attenuated Measles Vaccine Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Live Attenuated Measles Vaccine Revenue by Region
- 3.2.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Live Attenuated Measles Vaccine Revenue by Region (2020-2025)
- 3.2.3 Global Live Attenuated Measles Vaccine Revenue by Region (2026-2031)
- 3.2.4 Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2020-2031)
- 3.3 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts 2020-2031
- 3.4 Global Live Attenuated Measles Vaccine Sales by Region
- 3.4.1 Global Live Attenuated Measles Vaccine Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Live Attenuated Measles Vaccine Sales by Region (2020-2025)
- 3.4.3 Global Live Attenuated Measles Vaccine Sales by Region (2026-2031)
- 3.4.4 Global Live Attenuated Measles Vaccine Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers
- 4.1.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Live Attenuated Measles Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Live Attenuated Measles Vaccine Sales by Manufacturers
- 4.2.1 Global Live Attenuated Measles Vaccine Sales by Manufacturers (2020-2025)
- 4.2.2 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Live Attenuated Measles Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Live Attenuated Measles Vaccine Sales Price by Manufacturers (2020-2025)
- 4.4 Global Live Attenuated Measles Vaccine Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Live Attenuated Measles Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Live Attenuated Measles Vaccine Manufacturers, Product Type & Application
- 4.7 Global Live Attenuated Measles Vaccine Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Live Attenuated Measles Vaccine Market CR5 and HHI
- 4.8.2 2024 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3
- 5 Live Attenuated Measles Vaccine Market by Type
- 5.1 Global Live Attenuated Measles Vaccine Revenue by Type
- 5.1.1 Global Live Attenuated Measles Vaccine Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Live Attenuated Measles Vaccine Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2020-2031)
- 5.2 Global Live Attenuated Measles Vaccine Sales by Type
- 5.2.1 Global Live Attenuated Measles Vaccine Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Live Attenuated Measles Vaccine Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2020-2031)
- 5.3 Global Live Attenuated Measles Vaccine Price by Type
- 6 Live Attenuated Measles Vaccine Market by Application
- 6.1 Global Live Attenuated Measles Vaccine Revenue by Application
- 6.1.1 Global Live Attenuated Measles Vaccine Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Live Attenuated Measles Vaccine Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2020-2031)
- 6.2 Global Live Attenuated Measles Vaccine Sales by Application
- 6.2.1 Global Live Attenuated Measles Vaccine Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Live Attenuated Measles Vaccine Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2020-2031)
- 6.3 Global Live Attenuated Measles Vaccine Price by Application
- 7 Company Profiles
- 7.1 GSK
- 7.1.1 GSK Comapny Information
- 7.1.2 GSK Business Overview
- 7.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
- 7.1.5 GSK Recent Developments
- 7.2 Bavarian Nordic
- 7.2.1 Bavarian Nordic Comapny Information
- 7.2.2 Bavarian Nordic Business Overview
- 7.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
- 7.2.5 Bavarian Nordic Recent Developments
- 7.3 CSL Limited
- 7.3.1 CSL Limited Comapny Information
- 7.3.2 CSL Limited Business Overview
- 7.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
- 7.3.5 CSL Limited Recent Developments
- 7.4 Emergent Biosolutions
- 7.4.1 Emergent Biosolutions Comapny Information
- 7.4.2 Emergent Biosolutions Business Overview
- 7.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
- 7.4.5 Emergent Biosolutions Recent Developments
- 7.5 Medimmune
- 7.5.1 Medimmune Comapny Information
- 7.5.2 Medimmune Business Overview
- 7.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
- 7.5.5 Medimmune Recent Developments
- 7.6 Sanofi-Pasteur
- 7.6.1 Sanofi-Pasteur Comapny Information
- 7.6.2 Sanofi-Pasteur Business Overview
- 7.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
- 7.6.5 Sanofi-Pasteur Recent Developments
- 7.7 Serum Institute of India
- 7.7.1 Serum Institute of India Comapny Information
- 7.7.2 Serum Institute of India Business Overview
- 7.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
- 7.7.5 Serum Institute of India Recent Developments
- 7.8 Beijing Institute of Biological Products Co., Ltd
- 7.8.1 Beijing Institute of Biological Products Co., Ltd Comapny Information
- 7.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
- 7.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
- 7.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
- 7.9 Pfizer
- 7.9.1 Pfizer Comapny Information
- 7.9.2 Pfizer Business Overview
- 7.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
- 7.9.5 Pfizer Recent Developments
- 7.10 Lanzhou Institute of Biological Products Co., Ltd
- 7.10.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
- 7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
- 7.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
- 7.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
- 7.11 Merck
- 7.11.1 Merck Comapny Information
- 7.11.2 Merck Business Overview
- 7.11.3 Merck Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
- 7.11.5 Merck Recent Developments
- 7.12 Novartis
- 7.12.1 Novartis Comapny Information
- 7.12.2 Novartis Business Overview
- 7.12.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
- 7.12.5 Novartis Recent Developments
- 7.13 Johnson & Johnson
- 7.13.1 Johnson & Johnson Comapny Information
- 7.13.2 Johnson & Johnson Business Overview
- 7.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
- 7.13.5 Johnson & Johnson Recent Developments
- 7.14 Shanghai Institute of Biological Products Co., Ltd
- 7.14.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
- 7.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
- 7.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
- 7.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
- 7.15 Wuhan Institute of Biological Products Co., Ltd
- 7.15.1 Wuhan Institute of Biological Products Co., Ltd Comapny Information
- 7.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
- 7.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
- 7.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
- 7.16 Changchun Qijian Biological Products Co., Ltd
- 7.16.1 Changchun Qijian Biological Products Co., Ltd Comapny Information
- 7.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
- 7.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
- 7.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
- 8 North America
- 8.1 North America Live Attenuated Measles Vaccine Market Size by Type
- 8.1.1 North America Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
- 8.1.2 North America Live Attenuated Measles Vaccine Sales by Type (2020-2031)
- 8.1.3 North America Live Attenuated Measles Vaccine Price by Type (2020-2031)
- 8.2 North America Live Attenuated Measles Vaccine Market Size by Application
- 8.2.1 North America Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
- 8.2.2 North America Live Attenuated Measles Vaccine Sales by Application (2020-2031)
- 8.2.3 North America Live Attenuated Measles Vaccine Price by Application (2020-2031)
- 8.3 North America Live Attenuated Measles Vaccine Market Size by Country
- 8.3.1 North America Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Live Attenuated Measles Vaccine Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Live Attenuated Measles Vaccine Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 9 Europe
- 9.1 Europe Live Attenuated Measles Vaccine Market Size by Type
- 9.1.1 Europe Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
- 9.1.2 Europe Live Attenuated Measles Vaccine Sales by Type (2020-2031)
- 9.1.3 Europe Live Attenuated Measles Vaccine Price by Type (2020-2031)
- 9.2 Europe Live Attenuated Measles Vaccine Market Size by Application
- 9.2.1 Europe Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
- 9.2.2 Europe Live Attenuated Measles Vaccine Sales by Application (2020-2031)
- 9.2.3 Europe Live Attenuated Measles Vaccine Price by Application (2020-2031)
- 9.3 Europe Live Attenuated Measles Vaccine Market Size by Country
- 9.3.1 Europe Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Live Attenuated Measles Vaccine Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Live Attenuated Measles Vaccine Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 10 China
- 10.1 China Live Attenuated Measles Vaccine Market Size by Type
- 10.1.1 China Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
- 10.1.2 China Live Attenuated Measles Vaccine Sales by Type (2020-2031)
- 10.1.3 China Live Attenuated Measles Vaccine Price by Type (2020-2031)
- 10.2 China Live Attenuated Measles Vaccine Market Size by Application
- 10.2.1 China Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
- 10.2.2 China Live Attenuated Measles Vaccine Sales by Application (2020-2031)
- 10.2.3 China Live Attenuated Measles Vaccine Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Live Attenuated Measles Vaccine Market Size by Type
- 11.1.1 Asia Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
- 11.1.2 Asia Live Attenuated Measles Vaccine Sales by Type (2020-2031)
- 11.1.3 Asia Live Attenuated Measles Vaccine Price by Type (2020-2031)
- 11.2 Asia Live Attenuated Measles Vaccine Market Size by Application
- 11.2.1 Asia Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
- 11.2.2 Asia Live Attenuated Measles Vaccine Sales by Application (2020-2031)
- 11.2.3 Asia Live Attenuated Measles Vaccine Price by Application (2020-2031)
- 11.3 Asia Live Attenuated Measles Vaccine Market Size by Country
- 11.3.1 Asia Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Live Attenuated Measles Vaccine Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Live Attenuated Measles Vaccine Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Live Attenuated Measles Vaccine Market Size by Type
- 12.1.1 SAMEA Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
- 12.1.2 SAMEA Live Attenuated Measles Vaccine Sales by Type (2020-2031)
- 12.1.3 SAMEA Live Attenuated Measles Vaccine Price by Type (2020-2031)
- 12.2 SAMEA Live Attenuated Measles Vaccine Market Size by Application
- 12.2.1 SAMEA Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
- 12.2.2 SAMEA Live Attenuated Measles Vaccine Sales by Application (2020-2031)
- 12.2.3 SAMEA Live Attenuated Measles Vaccine Price by Application (2020-2031)
- 12.3 SAMEA Live Attenuated Measles Vaccine Market Size by Country
- 12.3.1 SAMEA Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Live Attenuated Measles Vaccine Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Live Attenuated Measles Vaccine Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Live Attenuated Measles Vaccine Value Chain Analysis
- 13.1.1 Live Attenuated Measles Vaccine Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Live Attenuated Measles Vaccine Production Mode & Process
- 13.2 Live Attenuated Measles Vaccine Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Live Attenuated Measles Vaccine Distributors
- 13.2.3 Live Attenuated Measles Vaccine Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.